Compare PRIM & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRIM | PCVX |
|---|---|---|
| Founded | 1960 | 2013 |
| Country | United States | United States |
| Employees | 18526 | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 7.0B |
| IPO Year | 2006 | 2020 |
| Metric | PRIM | PCVX |
|---|---|---|
| Price | $103.72 | $46.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 4 |
| Target Price | ★ $155.20 | $88.25 |
| AVG Volume (30 Days) | ★ 1.8M | 1.4M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.19% | N/A |
| EPS Growth | ★ 51.66 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.92 | N/A |
| Revenue Next Year | $8.80 | N/A |
| P/E Ratio | $383.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $71.84 | $29.10 |
| 52 Week High | $205.50 | $65.00 |
| Indicator | PRIM | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 35.39 | 37.28 |
| Support Level | $100.83 | $46.39 |
| Resistance Level | $122.33 | $49.46 |
| Average True Range (ATR) | 8.44 | 1.94 |
| MACD | 0.55 | -0.03 |
| Stochastic Oscillator | 9.42 | 18.82 |
Primoris Services Corp is a provider of critical infrastructure services operating mainly in the United States and Canada. The company provides a range of construction, maintenance, replacement, and engineering services. The Utilities segment operates throughout the United States and specializes in a range of services, including the construction and maintenance of new and existing natural gas and electric utility distribution and transmission systems, and communications systems. The Energy segment operates throughout the United States and Canada and specializes in a range of services that include engineering, procurement, construction, and maintenance services to various industries. The majority of the company's revenue is derived from the Energy segment.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.